Cancer stem cells in colorectal cancer from pathogenesis to therapy: Controversies and perspectives

World Journal of Gastroenterology

Volumn 20, Issue 4, 2014, Pages 923-942

  Fanali, Caterina ^a   Lucchetti, Donatella ^a   Farina, Marisa ^a   Corbi, Maddalena ^a   Cufino, Valerio ^a   Cittadini, Achille ^a   Sgambato, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer stem cells; Cancer therapy; Colorectal cancer; Prognostic marker; Tumorigenesis

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA CATENIN; BETA1 INTEGRIN; CD133 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 4; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER STEM CELL; CELL PROLIFERATION; COLON POLYPOSIS; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DISEASE COURSE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC PREDISPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK FACTOR; TUMOR GROWTH;

CANCER STEM CELLS; CANCER THERAPY; COLORECTAL CANCER; PROGNOSTIC MARKER; TUMORIGENESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84892991589     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i4.923     Document Type: Article

References (131)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403 [PMID: 23485231 DOI: 10.1016/j.ejca.2012.12.027]
2. McDonald SA, Preston SL, Lovell MJ, Wright NA, Jankowski JA. Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 267-274 [PMID: 16673006 DOI: 10.1038/ncpgasthep0473]
3. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell 2007; 128: 445-458 [PMID: 17289566 DOI: 10.1016/j.cell.2007.01.014]
4. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]
5. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40: 915-920 [PMID: 18536716 DOI: 10.1038/ng.165]
6. Moore KA, Lemischka IR. Stem cells and their niches. Science 2006; 311: 1880-1885 [PMID: 16574858 DOI: 10.1126/science. 1110542]
7. Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011; 474: 318-326 [PMID: 21677748 DOI: 10.1038/nature10212]
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
9. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003; 17: 1709-1713 [PMID: 12865297 DOI: 10.1101/gad.267103Genes]
10. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997; 275: 1784-1787 [PMID: 9065401 DOI: 10.1126/science.275.5307.1784]
11. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004; 303: 1684-1686 [PMID: 15017003 DOI: 10.1126/science. 1093587]
12. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004; 36: 1117-1121 [PMID: 15378062 DOI: 10.1038/ng1430]
13. Dexter DL, Spremulli EN, Fligiel Z, Barbosa JA, Vogel R, VanVoorhees A, Calabresi P. Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med 1981; 71: 949-956 [PMID: 7315857 DOI: 10.1016/0002-9343(81)90312-0]
14. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008; 105: 13427-13432 [PMID: 18765800 DOI: 10.1073/pnas.0805706105]
15. Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, Russo P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 2009; 16: 1688-1703 [PMID: 19442140 DOI: 10.2174/092986709788186147]
16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115 [PMID: 17122771 DOI: 10.1038/nature05384]
17. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110 [PMID: 17122772 DOI: 10.1038/nature05372]
18. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163 [PMID: 17548814 DOI: 10.1073/pnas.0703478104]
19. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006; 131: 630-639 [PMID: 16890615 DOI: 10.1053/j.gastro.2006.04.028]
20. Fujimoto K, Beauchamp RD, Whitehead RH. Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression. Gastroenterology 2002; 123: 1941-1948 [PMID: 12454851 DOI: 10.1053/gast.2002.37065]
21. Barker N, Clevers H. Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells. Gastroenterology 2010; 138: 1681-1696 [PMID: 20417836 DOI: 10.1053/j.gastro.2010.03.002]
22. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021 [PMID: 9389721]
23. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967 [PMID: 9020076 DOI: 10.1126/science. 275.5302.964]
24. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787 [PMID: 16990548 DOI: 10.1126/science.1127592]
25. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013; 229: 355-378 [PMID: 22899341 DOI: 10.1002/path.4086]
26. Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A, Piscaglia AC, Lauritano C, Novi ML, Barbaro F, Rinninella E, Campanale C, Giuliante F, Nuzzo G, Alfieri S, Doglietto GB, Cittadini A, Gasbarrini A. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1: 55-62 [PMID: 19530513]
27. Marzesco AM, Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005; 118: 2849-2858 [PMID: 15976444 DOI: 10.1016/j.febslet.2009.01.048]
28. Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J Cell Physiol 2010; 224: 234-241 [PMID: 20333645 DOI: 10.1002/jcp.22124]
29. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120 [PMID: 18497886 DOI: 10.1172/JCI34401]
30. Feng JM, Miao ZH, Jiang Y, Chen Y, Li JX, Tong LJ, Zhang J, Huang YR, Ding J. Characterization of the conversion between CD133+ and CD133-cells in colon cancer SW620 cell line. Cancer Biol Ther 2012; 13: 1396-1406 [PMID: 22954703 DOI: 10.4161/cbt.22000]
31. Hsu CS, Tung CY, Yang CY, Lin CH. Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620. PLoS One 2013; 8: e61133 [PMID: 23577199 DOI: 10.1371/journal.pone.0061133]
32. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008; 99: 1578-1583 [PMID: 18754869 DOI: 10.1111/j.1349-7006.2008.00849.x]
33. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99: 1285-1289 [PMID: 18781171 DOI: 10.1038/sj.bjc.6604664]
34. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010; 23: 450-457 [PMID: 20081809 DOI: 10.1038/modpathol.2009.181]
35. Kawamoto A, Tanaka K, Saigusa S, Toiyama Y, Morimoto Y, Fujikawa H, Iwata T, Matsushita K, Yokoe T, Yasuda H, Inoue Y, Miki C, Kusunoki M. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 2012; 3: 403-409 [PMID: 22969903 DOI: 10.3892/etm.2011.438]
36. Chao C, Carmical JR, Ives KL, Wood TG, Aronson JF, Gomez GA, Djukom CD, Hellmich MR. CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133-cells. Lab Invest 2012; 92: 420-436 [PMID: 22157717 DOI: 10.1038/labinvest.2011.185]
37. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L, Wei LX. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012; 10: 85 [PMID: 22871210 DOI: 10.1186/1741-7015-10-85]
38. Kemper K, Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res 2012; 18: 3132-3141 [PMID: 22496204 DOI: 10.1158/1078-0432.CCR-11-3066]
39. Mohammadi M, Bzorek M, Bonde JH, Nielsen HJ, Holck S. The stem cell marker CD133 is highly expressed in sessile serrated adenoma and its borderline variant compared with hyperplastic polyp. J Clin Pathol 2013; 66: 403-408 [PMID: 23436931 DOI: 10.1136/jclinpath-2012-201192]
40. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, Cittadini A, Sgambato A. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res 2012; 31: 71 [PMID: 22964035 DOI: 10.1186/1756-9966-31-71]
41. Sgambato A, Errico F, Caredda E, Puglisi MA, Cittadini A. Divergent expression of CD133 in different studies: the need for a consensus panel? Int J Cancer 2011; 128: 2247-2249 [PMID: 20626045 DOI: 10.1002/ijc.25551]
42. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457: 603-607 [PMID: 19092805 DOI: 10.1038/nature07589]
43. Arena V, Caredda E, Cufino V, Stigliano E, Scaldaferri F, Gasbarrini A, Cittadini A, Sgambato A. Differential CD133 expression pattern during mouse colon tumorigenesis. Anticancer Res 2011; 31: 4273-4275 [PMID: 22199291]
44. Sgambato A, Corbi M, Svelto M, Caredda E, Cittadini A. New Insights into the CD133 (Prominin-1) Expression in Mouse and Human Colon Cancer Cells. Adv Exp Med Biol 2013; 777: 145-166 [PMID: 23161081 DOI: 10.1007/978-1-4614-5894-4_10]
45. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X, Jiang J. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA 2013; 110: 6829-6834 [PMID: 23569237 DOI: 10.1073/pnas.1217002110]
46. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010; 31: 1376-1380 [PMID: 20530554 DOI: 10.1093/carcin/bgq120]
47. Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC. Silibinin suppresses the maintenance of colorectal cancer stemlike cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 2012; 113: 1733-1743 [PMID: 22213051 DOI: 10.1002/jcb.24043]
48. Corbo C, Orrù S, Gemei M, Noto RD, Mirabelli P, Imperlini E, Ruoppolo M, Vecchio LD, Salvatore F. Protein crosstalk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. Proteomics 2012; 12: 2045-2059 [PMID: 22623141 DOI: 10.1002/pmic.201100370]
49. Ou J, Deng J, Wei X, Xie G, Zhou R, Yu L, Liang H. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res 2013; 11: 820-833 [PMID: 23811539 DOI: 10.1016/j.scr.2013.05.009]
50. Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, Moffat J. Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep 2012; 2: 951-963 [PMID: 23084749 DOI: 10.1016/j.celrep.2012.09.016]
51. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010; 176: 2292-2301 [PMID: 20363910 DOI: 10.2353/ajpath.2010.090972]
52. Ohnishi S, Maehara O, Nakagawa K, Kameya A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, Sakamoto N, Kobayashi M, Takeda H. hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors. PLoS One 2013; 8: e66255 [PMID: 23840432 DOI: 10.1371/journal.pone.0066255]
53. Mao Q, Zhang Y, Fu X, Xue J, Guo W, Meng M, Zhou Z, Mo X, Lu Y. A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol 2013; 139: 211-222 [PMID: 23052691 DOI: 10.1007/s00432-012-1310-3]
54. Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008; 68: 8094-8103 [PMID: 18829568 DOI: 10.1158/0008-5472.CAN-07-6208]
55. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164 [PMID: 1465456 DOI: 10.1073/pnas.89.24.12160]
56. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998; 51: 191-200 [PMID: 9893744 DOI: 10.1136/mp.51.4.191]
57. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-935 [PMID: 15596040 DOI: 10.1111/j.1349-7006.2004.tb03179.x]
58. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14: 6751-6760 [PMID: 18980968 DOI: 10.1158/1078-0432. CCR-08-1034]
59. Fan CW, Chen T, Shang YN, Gu YZ, Zhang SL, Lu R, OuYang SR, Zhou X, Li Y, Meng WT, Hu JK, Lu Y, Sun XF, Bu H, Zhou ZG, Mo XM. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. Cell Death Dis 2013; 4: e828 [PMID: 24091671 DOI: 10.1038/cddis.2013.337]
60. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68: 3655-3661 [PMID: 18483247 DOI: 10.1158/0008-5472.CAN-07-2940]
61. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001; 91: 67-75 [PMID: 11149422 DOI: 10.1002/1097-0215(20010101)91: 1<67::AIDIJC1011> 3.0.CO;2-D]
62. Dallas MR, Liu G, Chen WC, Thomas SN, Wirtz D, Huso DL, Konstantopoulos K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J 2012; 26: 2648-2656 [PMID: 22415308 DOI: 10.1096/fj.12-203786]
63. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 1998; 33: 301-309 [PMID: 9548625 DOI: 10.1080/00365529850170900]
64. Ylagan LR, Scholes J, Demopoulos R. Cd44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 2000; 124: 212-215 [PMID: 10656728]
65. Fernández JC, Vizoso FJ, Corte MD, Gava RR, Corte MG, Suárez JP, García-Muñíz JL, García-Morán M. CD44s expression in resectable colorectal carcinomas and surrounding mucosa. Cancer Invest 2004; 22: 878-885 [PMID: 15641486 DOI: 10.1081/CNV-200039658]
66. Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009; 59: 241-246 [PMID: 19351367 DOI: 10.1111/j.1440-1827.2009.02357.x]
67. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010; 103: 382-390 [PMID: 20606680 DOI: 10.1038/sj.bjc.6605762]
68. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76: 1438-1442 [PMID: 286328 DOI: 10.1073/pnas.76.3.1438]
69. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-135 [PMID: 16404366 DOI: 10.1038/sj.bjc.6602924]
70. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007; 96: 417-423 [PMID: 17211480 DOI: 10.1038/sj.bjc.6603494]
71. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171: 386-395 [PMID: 17600130 DOI: 10.2353/ajpath.2007.070152]
72. Denzel S, Maetzel D, Mack B, Eggert C, Bärr G, Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009; 9: 402 [PMID: 19925656 DOI: 10.1186/1471-2407-9-402]
73. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV. The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 1999; 246: 108-121 [PMID: 9882520 DOI: 10.1006/excr.1998.4263]
74. Ralhan R, He HC, So AK, Tripathi SC, Kumar M, Hasan MR, Kaur J, Kashat L, MacMillan C, Chauhan SS, Freeman JL, Walfish PG. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One 2010; 5: e14130 [PMID: 21152431 DOI: 10.1371/journal. pone.0014130]
75. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3: e2428 [PMID: 18560594 DOI: 10.1371/journal. pone.0002428]
76. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35: 255-262 [PMID: 15339045 DOI: 10.1023/B: HIJO.0000032357.16261.c5]
77. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001; 61: 1569-1577 [PMID: 11245467]
78. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11: 6574-6581 [PMID: 16166435 DOI: 10.1158/1078-0432. CCR-05-0606]
79. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009; 15: 2258-2264 [PMID: 19437567 DOI: 10.3748/wjg.15.2258]
80. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010; 107: 3722-3727 [PMID: 20133591 DOI: 10.1073/pnas.0915135107]
81. Muppala S, Mudduluru G, Leupold JH, Buergy D, Sleeman JP, Allgayer H. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One 2013; 8: e59563 [PMID: 23533633 DOI: 10.1371/journal.pone.0059563]
82. Brizzi MF, Tarone G, Defilippi P. Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche. Curr Opin Cell Biol 2012; 24: 645-651 [PMID: 22898530 DOI: 10.1016/j.ceb.2012.07.001]
83. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687 [PMID: 12297042 DOI: 10.1016/S0092-8674(02)00971-6]
84. Pignatelli M, Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br J Cancer 1992; 66: 629-634 [PMID: 1384639 DOI: 10.1038/bjc.1992.328]
85. Okazaki K, Nakayama Y, Shibao K, Hirata K, Nagata N, Itoh H. Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. J Surg Res 1998; 78: 78-84 [PMID: 9733622 DOI: 10.1006/jsre.1998.5298]
86. Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF. Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis 2010; 25: 17-23 [PMID: 19714342 DOI: 10.1007/s00384-009-0791-2]
87. Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer 2012; 3: 231-240 [PMID: 22670157 DOI: 10.7150/jca.4542]
88. Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, Kitayama J, Takahashi K, Nagawa H. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling. J Surg Res 2012; 175: 278-288 [PMID: 21601882 DOI: 10.1016/j.jss.2011.03.076]
89. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H. The Intestinal Wnt/TCF Signature. Gastroenterology 2007; 132: 628-632 [PMID: 17320548 DOI: 10.1053/j.gastro.2006.08.039]
90. de Lau WB, Snel B, Clevers HC. The R-spondin protein family. Genome Biol 2012; 13: 242 [PMID: 22439850 DOI: 10.1186/gb-2012-13-3-242]
91. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The betacatenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250 [PMID: 12408868 DOI: 10.1016/S0092-8674(02)01014-0]
92. Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 2012; 10: 244 [PMID: 23153436 DOI: 10.11 86/1477-7819-10-244]
93. Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol 2009; 174: 715-721 [PMID: 19197002 DOI: 10.2353/ajpath.2009.080758]
94. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y, Mori M. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 2011; 18: 1166-1174 [PMID: 21125339 DOI: 10.1245/s10434-010-1373-9]
95. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263 [PMID: 12408869 DOI: 10.1016/S0092-8674(02)01015-2]
96. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-9895 [PMID: 2602381 DOI: 10.1073/pnas.86.24.9891]
97. Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J. CD6-ligand interactions: a paradigm for SRCR domain function? Immunol Today 1997; 18: 498-504 [PMID: 9357143 DOI: 10.1016/S0167-5699(97)01130-4]
98. Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 2010; 7: 231-243 [PMID: 20952758]
99. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 2010; 139: 2072-2082. e5 [PMID: 20826154 DOI: 10.1053/j.gastro.2010.08.053]
100. Weichert W, Knösel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57: 1160-1164 [PMID: 15509676 DOI: 10.1136/jcp.2004.016238]
101. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009; 27: 844-850 [PMID: 19626493 DOI: 10.1080/07357900902744502]
102. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, Bockhorn M. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients. J Surg Res 2012; 177: e15-e20 [PMID: 22482754 DOI: 10.1016/j.jss.2012.02.013]
103. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50 [PMID: 20051635 DOI: 10.1172/JCI41004]
104. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402 [PMID: 18371377 DOI: 10.1016/j.stem.2007.08.001]
105. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957 [PMID: 19244128 DOI: 10.1158/0008-5472.CAN-08-2023]
106. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 2013; 73: 865-874 [PMID: 23293278 DOI: 10.1158/0008-5472. CAN-12-2221]
107. Bostad M, Berg K, Høgset A, Skarpen E, Stenmark H, Selbo PK. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties. J Control Release 2013; 168: 317-326 [PMID: 23567040 DOI: 10.1016/j.jconrel.2013.03.023]
108. Chen H, Luo Z, Sun W, Zhang C, Sun H, Zhao N, Ding J, Wu M, Li Z, Wang H. Low glucose promotes CD133mAbelicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer Lett 2013; 336: 204-212 [PMID: 23652197 DOI: 10.1016/j.canlet.2013.04.031]
109. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 2013; 171: 280-287 [PMID: 23871962 DOI: 10.1016/j.jconrel.2013.07.014]
110. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994; 343: 1177-1183 [PMID: 7909866 DOI: 10.1016/S0140-6736(94)92398-1]
111. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360: 671-677 [PMID: 12241873 DOI: 10.1016/S0140-6736(02)09836-7]
112. Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009; 27: 1941-1947 [PMID: 19273708 DOI: 10.1200/JCO.2008.18.5710]
113. Waldron NN, Barsky SH, Dougherty PR, Vallera DA. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol 2013; Epub ahead of print [PMID: 23900680]
114. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem 2009; 284: 12432-12446 [PMID: 19246453 DOI: 10.1074/jbc.M806772200]
115. Nautiyal J, Kanwar SS, Yu Y, Majumdar AP. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal 2011; 6: 7 [PMID: 21774804 DOI: 10.1186/1750-2187-6-7]
116. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, Majumdar AP. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stemlike cells. Pharm Res 2011; 28: 827-838 [PMID: 21161336 DOI: 10.1007/s11095-010-0336-y]
117. Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale 2013; 5: 178-183 [PMID: 23076766 DOI: 10.1039/c2nr32145a]
118. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008; 68: 2803-2812 [PMID: 18413748 DOI: 10.1158/0008-5472.CAN-07-6463]
119. Park JJ, Seo SM, Kim EJ, Lee YJ, Ko YG, Ha J, Lee M. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin β1 signaling. Biochem Biophys Res Commun 2012; 426: 461-467 [PMID: 22943849 DOI: 10.1016/j.bbrc.2012.08.091]
120. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-642 [PMID: 8757136 DOI: 10.1038/382638a0]
121. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5: 100-107 [PMID: 19125156 DOI: 10.1038/nchembio.137]
122. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620 [PMID: 19759537 DOI: 10.1038/nature08356]
123. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM, Lee E. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 2010; 6: 829-836 [PMID: 20890287 DOI: 10.1038/nchembio.453]
124. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, DasGupta R. An RNAi-based chemical genetic screen identifies three smallmolecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA 2011; 108: 5954-5963 [PMID: 21393571 DOI: 10.1073/pnas.1017496108]
125. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101: 12682-12687 [PMID: 15314234 DOI: 10.1073/pnas.0404875101]
126. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-3162 [PMID: 20530697 DOI: 10.1158/1078-0432. CCR-09-2943]
127. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6: 7-14 [PMID: 15068666]
128. Ueno K, Hazama S, Mitomori S, Nishioka M, Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 2009; 101: 1374-1381 [PMID: 19773752 DOI: 10.1038/sj.bjc.6605307]
129. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26 [PMID: 23258168 DOI: 10.1038/nrc3419]
130. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5: 168-177 [PMID: 19664991 DOI: 10.1016/j.stem.2009.05.019]
131. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011; 71: 1520-1525 [PMID: 21193546 DOI: 10.1158/0008-5472. CAN-10-2817]